Drug profile · INN
galcanezumab
EMGALITY
galcanezumab (EMGALITY) is a calcitonin gene-related peptide inhibitor.
EMA: approved TGA: approved PMDA: approved Nervous system (N02) N02
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — galcanezumab
- Class
- Nervous system (N02)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
galcanezumab (EMGALITY) is a calcitonin gene-related peptide inhibitor.
Key facts
INN galcanezumab
Brand EMGALITY
Mechanism Calcitonin gene-related peptide inhibitor
Target Calcitonin gene-related peptide
Therapeutic class Nervous system (N02)
ATC code N02
Mechanism of action
Calcitonin gene-related peptide inhibitor
Primary target: Calcitonin gene-related peptide
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is galcanezumab?
galcanezumab (EMGALITY) is a calcitonin gene-related peptide inhibitor.
What is the brand name for galcanezumab?
EMGALITY is a marketed brand name for galcanezumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.